U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from MedGen

Items: 1 to 20 of 30

1.
Role of serine 365 in BRAF V600E sensitivity to RAF inhibition
Michael J. Vido, Justin Rock, Andrew E. Aplin
Pigment Cell Melanoma Res. Author manuscript; available in PMC 2021 Jul 16.
Published in final edited form as: Pigment Cell Melanoma Res. 2021 Jul; 34(4): 696–702. Published online 2020 Oct 14. doi: 10.1111/pcmr.12932
PMCID:
PMC8285005
AbstractArticlePDF–636K
2.
Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
Monika Joshi, Shawn J. Rice, Xin Liu, Bruce Miller, Chandra P. Belani
PLoS One. 2015; 10(2): e0118210. Published online 2015 Feb 23. doi: 10.1371/journal.pone.0118210
PMCID:
PMC4338247
AbstractArticlePDF–1.3M
3.
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer
Ross A. Okimoto, Luping Lin, Victor Olivas, Elton Chan, Evan Markegard, Andrey Rymar, Dana Neel, Xiao Chen, Golzar Hemmati, Gideon Bollag, Trever G. Bivona
Proc Natl Acad Sci U S A. 2016 Nov 22; 113(47): 13456–13461. Published online 2016 Nov 9. doi: 10.1073/pnas.1610456113
PMCID:
PMC5127364
AbstractArticlePDF–1.2M
4.
Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights
Rodrigo Dienstmann, Elena Elez, Guillem Argiles, Ignacio Matos, Enrique Sanz‐Garcia, Carolina Ortiz, Teresa Macarulla, Jaume Capdevila, Maria Alsina, Tamara Sauri, Helena Verdaguer, Marta Vilaro, Fiorella Ruiz‐Pace, Cristina Viaplana, Ariadna Garcia, Stefania Landolfi, Hector G. Palmer, Paolo Nuciforo, Jordi Rodon, Ana Vivancos, Josep Tabernero
Mol Oncol. 2017 Sep; 11(9): 1263–1272. Published online 2017 Jul 20. doi: 10.1002/1878-0261.12099
PMCID:
PMC5579330
AbstractArticlePDF–506K
5.
Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
Eszter Molnár, Dominika Rittler, Marcell Baranyi, Michael Grusch, Walter Berger, Balázs Döme, József Tóvári, Clemens Aigner, József Tímár, Tamás Garay, Balázs Hegedűs
BMC Cancer. 2018; 18: 542. Published online 2018 May 8. doi: 10.1186/s12885-018-4455-x
PMCID:
PMC5941622
AbstractArticlePDF–1.5M
6.
Hybrid Capture‐Based Genomic Profiling Identifies BRAF V600 and Non‐V600 Alterations in Melanoma Samples Negative by Prior Testing
Lise Boussemart, Annie Nelson, Michael Wong, Jeffrey S. Ross, Jeffrey Sosman, Janice Mehnert, Gregory Daniels, Kari Kendra, Siraj Mahamed Ali, Vincent A. Miller, Alexa B. Schrock
Oncologist. 2019 May; 24(5): 657–663. Published online 2019 Jan 25. doi: 10.1634/theoncologist.2018-0271
PMCID:
PMC6516121
AbstractArticlePDF–783K
7.
Response to anti-EGFR therapy in patients with BRAF non-V600 mutant metastatic colorectal cancer
Rona Yaeger, Daisuke Kotani, Sebastián Mondaca, Aparna Parikh, Hideaki Bando, Emily Van Seventer, Hiroya Taniguchi, HuiYong Zhao, Claire Thant, Elisa de Stanchina, Neal Rosen, Ryan B. Corcoran, Takayuki Yoshino, Zhan Yao, Hiromichi Ebi
Clin Cancer Res. Author manuscript; available in PMC 2020 Jun 1.
Published in final edited form as: Clin Cancer Res. 2019 Dec 1; 25(23): 7089–7097. Published online 2019 Sep 12. doi: 10.1158/1078-0432.CCR-19-2004
PMCID:
PMC6891165
AbstractArticlePDF–715K
8.
Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: results from NCI-MATCH (EAY131)
Douglas B. Johnson, Fengmin Zhao, Marcus Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright, Helen X. Chen, Robert J. Gray, Shuli Li, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanly R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, Alice P. Chen, Keith T. Flaherty
Clin Cancer Res. Author manuscript; available in PMC 2020 Oct 15.
Published in final edited form as: Clin Cancer Res. 2020 Apr 15; 26(8): 1812–1819. Published online 2020 Jan 10. doi: 10.1158/1078-0432.CCR-19-3443
PMCID:
PMC7165046
AbstractArticlePDF–800K
9.
Spitz Melanoma is a Distinct Subset of Spitzoid Melanoma
Shyam Raghavan, Sandra Peternel, Thaddeus W. Mully, Jeffrey P. North, Laura B. Pincus, Philip E. LeBoit, Timothy H. McCalmont, Boris C. Bastian, Iwei Yeh
Mod Pathol. Author manuscript; available in PMC 2020 Jul 3.
Published in final edited form as: Mod Pathol. 2020 Jun; 33(6): 1122–1134. Published online 2020 Jan 3. doi: 10.1038/s41379-019-0445-z
PMCID:
PMC7286778
AbstractArticlePDF–6.0M
10.
Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations
Marcelo V. Negrao, Victoria M. Raymond, Richard B. Lanman, Jacqulyne P. Robichaux, Junqin He, Monique B. Nilsson, Patrick K. S. Ng, Bianca E. Amador, Emily B. Roarty, Rebecca J. Nagy, Kimberly C. Banks, Viola W. Zhu, Chun Ng, Young Kwang Chae, Jeffrey M. Clarke, Jeffrey A. Crawford, Funda Meric-Bernstam, Sai-Hong Ou, David R. Gandara, John V. Heymach, Trever G. Bivona, Caroline E. McCoach
J Thorac Oncol. Author manuscript; available in PMC 2021 Oct 1.
Published in final edited form as: J Thorac Oncol. 2020 Oct; 15(10): 1611–1623. Published online 2020 Jun 13. doi: 10.1016/j.jtho.2020.05.021
PMCID:
PMC7529990
AbstractArticlePDF–1.2M
11.
Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer
Benny Johnson, Scott Kopetz
Target Oncol. Author manuscript; available in PMC 2021 Oct 1.
Published in final edited form as: Target Oncol. 2020 Oct; 15(5): 567–577. doi: 10.1007/s11523-020-00747-5
PMCID:
PMC7583680
AbstractArticlePDF–238K
12.
A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker
Alla Turshudzhyan, James Vredenburgh
Curr Oncol. 2021 Feb; 28(1): 196–202. Published online 2020 Dec 25. doi: 10.3390/curroncol28010021
PMCID:
PMC7816189
AbstractArticlePDF–780K
13.
Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity
Aayoung Hong, Marco Piva, Sixue Liu, Willy Hugo, Shirley H. Lomeli, Vincent Zoete, Christopher E. Randolph, Zhentao Yang, Yan Wang, Jordan J. Lee, Skylar J. Lo, Lu Sun, Agustin Vega-Crespo, Alejandro J. Garcia, David B. Shackelford, Steven M. Dubinett, Philip O. Scumpia, Stephanie D. Byrum, Alan J. Tackett, Timothy R. Donahue, Olivier Michielin, Sheri L. Holmen, Antoni Ribas, Gatien Moriceau, Roger S. Lo
Cancer Discov. Author manuscript; available in PMC 2021 Sep 1.
Published in final edited form as: Cancer Discov. 2021 Mar; 11(3): 714–735. Published online 2020 Dec 14. doi: 10.1158/2159-8290.CD-20-0873
Expression of Concern in:
Cancer Discov. 2024 Jul 1; 14(7): 1357.
PMCID:
PMC7933113
AbstractArticlePDF–4.3M
14.
Novel and Potent Small Molecules against Melanoma Harboring BRAF Class I/II/III Mutants for Overcoming Drug Resistance
Namkyoung Kim, Injae Shin, Jiwon Lee, Eunhye Jeon, Younghoon Kim, Seongshick Ryu, Eunhye Ju, Wonjeong Cho, Taebo Sim
Int J Mol Sci. 2021 Apr; 22(7): 3783. Published online 2021 Apr 6. doi: 10.3390/ijms22073783
PMCID:
PMC8038755
AbstractArticlePDF–2.9M
15.
High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens
Lauren Y. Cheng, Lauren E. Haydu, Ping Song, Jianyi Nie, Michael T. Tetzlaff, Lawrence N. Kwong, Jeffrey E. Gershenwald, Michael A. Davies, David Yu Zhang
Sci Rep. 2021; 11: 9043. Published online 2021 Apr 27. doi: 10.1038/s41598-021-88391-5
PMCID:
PMC8079675
AbstractArticlePDF–3.5M
16.
A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Rona Yaeger, Meredith A. McKean, Rizwan Haq, J. Thaddeus Beck, Matthew H. Taylor, Jonathan E. Cohen, Daniel W. Bowles, Shirish M. Gadgeel, Catalin Mihalcioiu, Kyriakos P. Papadopoulos, Eli L. Diamond, Keren B. Sturtz, Gang Feng, Stefanie K. Drescher, Micaela B. Reddy, Bhaswati Sengupta, Arnab K. Maity, Suzy A. Brown, Anurag Singh, Eric N. Brown, Brian R. Baer, Jim Wong, Tung-Chung Mou, Wen-I Wu, Dean R. Kahn, Sunyana Gadal, Neal Rosen, John J. Gaudino, Patrice A. Lee, Dylan P. Hartley, S. Michael Rothenberg
Cancer Discov. 2024 Sep 4; 14(9): 1599–1611. Published online 2024 May 1. doi: 10.1158/2159-8290.CD-24-0024
PMCID:
PMC11372368
AbstractArticlePDF–10M
17.
Efficacy and Safety of Trametinib in Non‐V600 BRAF Mutant Melanoma: A Phase II Study
Caroline A. Nebhan, Douglas B. Johnson, Ryan J. Sullivan, Roda N. Amaria, Keith T. Flaherty, Jeffrey A. Sosman, Michael A. Davies
Oncologist. 2021 Sep; 26(9): 731–e1498. Published online 2021 May 4. doi: 10.1002/onco.13795
PMCID:
PMC8417872
AbstractArticlePDF–418K
18.
Targeted Therapy for Melanomas Without BRAF V600 Mutations
Christian Menzer, Jessica C. Hassel
Curr Treat Options Oncol. 2022; 23(6): 831–842. Published online 2022 Apr 5. doi: 10.1007/s11864-022-00946-4
PMCID:
PMC9042969
AbstractArticlePDF–260K
19.
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma
Zachary Wolfe, Julie C. Friedland, Sarah Ginn, Aaron Blackham, Lauren Demberger, Morgan Horton, Alyson McIntosh, Hina Sheikh, Jessica Box, Deborah Knoerzer, Bryan Federowicz, Timothy J. Stuhlmiller, Mark Shapiro, Suresh Nair
Melanoma Res. 2022 Aug; 32(4): 295–298. Published online 2022 May 12. doi: 10.1097/CMR.0000000000000830
PMCID:
PMC9245552
AbstractArticlePDF–550K
20.
Clinical associations and genetic interactions of oncogenic BRAF alleles
Sebastian A. Wagner
PeerJ. 2022; 10: e14126. Published online 2022 Oct 18. doi: 10.7717/peerj.14126
PMCID:
PMC9586110
AbstractArticlePDF–1.2M

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center